The British Liver Trust are pleased to be supporting the HCC-UK 2019 Conference “A Personalised Medicine Approach to Optimise Care in Hepatocellular Cancer”.
Hepatocellular carcinoma (HCC) is the most common form of liver cancer. In the UK there are more than 5,500 new cases of primary liver cancer diagnosed each year, which is around 15 patients each day. It is particularly aggressive with the 5-year survival rate being on average only 12% and a diagnosis is therefore devastating for the patient and their families.
Clinicians from the fields of hepatology, oncology, surgery, radiology, pathology and nursing will gather in Birmingham on 14th-15th March, with programme highlights including:
- Selection for transplant and surgery
- HCC in the setting of viral hepatitis
- New oncological therapies on the horizon
- Debate on early resection vs transplantation
- Research updates from around the UK
- The impact of dietetic input in HCC clinics